Affymax (AFFY)
Affymax Revenue Growth: 278.9%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AFFY Revenue Growth Rankings
| Overall | 98th percentile | 47 of 4389 |
| Sector | 95th percentile | 19 of 460 in Healthcare |
| Industry | 87th percentile | 16 of 126 in Biotechnology |
AFFY Revenue Growth Range, Past 5 Years
| Minimum | -79.57% | Dec 2010 |
| Maximum | 6757% | Jun 2007 |
| Average | 385.2% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these AFFY related companies
AFFY News
$AFFY http://stks.co/3w3g on watch list and now at the line - volume 17% of average full day
about a day ago by StockTiger
about a day ago by StockTiger
Streetinsider.com's Hot Lunchtime Reads 05/21: (AAPL) (FB) (LVS) (AFFY) (GDP)
May 21, 12:35PM Street Insider
May 21, 12:35PM Street Insider
$AFFY Not a dead cat bounce today. Continuation of uptrend. This stock was almost at $15 last week before the market got nasty.
about 2 days ago by chileeater
about 2 days ago by chileeater
Analyst Sees Affymax's (AFFY) Omontys as Comparable to Amgen's (AMGN) Epogen; Raises AFFY Target to $21
May 21, 12:17PM Street Insider
May 21, 12:17PM Street Insider
$AFFY http://stks.co/3r6w was out this AM but see this watch list stock hit trigger and doing ok so far
about 7 days ago by StockTiger
about 7 days ago by StockTiger
Market Wrap Video + Additions to Watch List http://stks.co/3qQd including: $FFN $LLNW $AFFY $GET $DHI $CTSH $SREV
about 8 days ago by StockTiger
about 8 days ago by StockTiger
RT @mydanilo $AFFY at previous high from March, going to be interesting __ It is going interestingly!
about 8 days ago by Glopolon
about 8 days ago by Glopolon
@SlownSteady @unusual7 $ARNA $VVUS See the commentary around $AMGN $AFFY, re: monopoly in marketplace.
about 11 days ago by Glopolon
about 11 days ago by Glopolon
Auriga Maintains a 'Buy' on Affymax, Inc. (AFFY); Milestone Payments Drive Q1 Upside; Continue Seeing Market Opp for Omontys
May 08, 10:42AM Street Insider
May 08, 10:42AM Street Insider
Affymax Announces First Quarter 2012 Financial Results Teleconference and Webcast
Apr 30, 4:00PM Business Wire
Apr 30, 4:00PM Business Wire
Affymax (AFFY), Takeda Announce CMS Assigned Q-Code for OMONTYS(R) Injection
Apr 13, 8:06AM Street Insider
Apr 13, 8:06AM Street Insider
Affymax, Inc. (AFFY) Received $50 Million Milestone Payment From Takeda Pharmaceutical
Apr 09, 4:01PM Street Insider
Apr 09, 4:01PM Street Insider
Affymax Receives a $50M Milestone Payment for U.S. Approval of OMONTYS Injection
Apr 09, 4:00PM Benzinga
Apr 09, 4:00PM Benzinga
Affymax Receives a $50 Million Milestone Payment for U.S. Approval of OMONTYS® (peginesatide) Injection
Apr 09, 4:00PM Business Wire
Apr 09, 4:00PM Business Wire
Visium Asset Management, LP Shows New 9.13% Stake in Affymax, Inc. (AFFY)
Apr 05, 4:20PM Street Insider
Apr 05, 4:20PM Street Insider
Affymax Analyst: Company Moving Higher on Momentum, Stock is Still Undervalued Here
Apr 05, 2:00PM Benzinga
Apr 05, 2:00PM Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AFFY | 14.19 | +0.02 | +0.14% | 506.86M |
| AEZS | 0.4699 | -0.01 | -2.10% | 50.77M |
| AETI | 4.52 | +0.04 | +0.89% | 35.08M |
| AER | 11.36 | -0.01 | -0.09% | 1.590B |
| AEP | 37.79 | -0.27 | -0.71% | 18.42B |
| AEM | 39.20 | +2.03 | +5.46% | 6.353B |
